Sernova Corp. (SEOVF)
USD 0.13
(0.15%)
USD 0.13
(0.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -41.13 Million CAD | -70.13% |
| 2022 | -24.17 Million CAD | -252.12% |
| 2021 | -6.86 Million CAD | -31.51% |
| 2020 | -5.22 Million CAD | -31.52% |
| 2019 | -3.96 Million CAD | -7.91% |
| 2018 | -3.67 Million CAD | -42.07% |
| 2017 | -2.58 Million CAD | -4.77% |
| 2016 | -2.47 Million CAD | 13.39% |
| 2015 | -2.85 Million CAD | -2.15% |
| 2014 | -2.79 Million CAD | -35.27% |
| 2013 | -2.06 Million CAD | 20.67% |
| 2012 | -2.6 Million CAD | -27.41% |
| 2011 | -2.04 Million CAD | -10.77% |
| 2010 | -1.84 Million CAD | -24.09% |
| 2009 | -1.48 Million CAD | 47.54% |
| 2008 | -2.83 Million CAD | 23.77% |
| 2007 | -3.71 Million CAD | -178.25% |
| 2006 | -1.33 Million CAD | -213.85% |
| 2005 | -425.66 Thousand CAD | 30.58% |
| 2004 | -613.21 Thousand CAD | 13.61% |
| 2003 | -709.85 Thousand CAD | 52.55% |
| 2002 | -1.49 Million CAD | 30.08% |
| 2001 | -2.13 Million CAD | -350.69% |
| 2000 | -474.8 Thousand CAD | -1452.61% |
| 1999 | -30.58 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.08 Million CAD | 12.41% |
| 2024 Q2 | -9.85 Million CAD | 2.27% |
| 2024 Q3 | -7.09 Million CAD | 27.43% |
| 2023 Q4 | -11.51 Million CAD | -15.93% |
| 2023 Q3 | -9.93 Million CAD | -5.62% |
| 2023 Q2 | -9.4 Million CAD | -15.43% |
| 2023 Q1 | -8.14 Million CAD | -1.41% |
| 2023 FY | -41.13 Million CAD | -70.13% |
| 2022 Q2 | -4.91 Million CAD | 9.63% |
| 2022 FY | -24.17 Million CAD | -252.12% |
| 2022 Q3 | -5.79 Million CAD | -17.84% |
| 2022 Q4 | -8.03 Million CAD | -38.74% |
| 2022 Q1 | -5.43 Million CAD | -122.77% |
| 2021 Q1 | -1.16 Million CAD | -19.52% |
| 2021 Q4 | -2.44 Million CAD | -51.28% |
| 2021 Q3 | -1.61 Million CAD | 2.23% |
| 2021 FY | -6.86 Million CAD | -31.51% |
| 2021 Q2 | -1.65 Million CAD | -42.08% |
| 2020 Q1 | -1.35 Million CAD | 22.86% |
| 2020 Q3 | -1.17 Million CAD | 31.48% |
| 2020 Q4 | -971.77 Thousand CAD | 17.29% |
| 2020 FY | -5.22 Million CAD | -31.52% |
| 2020 Q2 | -1.71 Million CAD | -26.1% |
| 2019 Q1 | -719.01 Thousand CAD | 13.42% |
| 2019 FY | -3.96 Million CAD | -7.91% |
| 2019 Q3 | -876.81 Thousand CAD | -43.71% |
| 2019 Q4 | -1.76 Million CAD | -101.04% |
| 2019 Q2 | -610.14 Thousand CAD | 15.14% |
| 2018 FY | -3.67 Million CAD | -42.07% |
| 2018 Q3 | -1.1 Million CAD | -12.73% |
| 2018 Q4 | -830.47 Thousand CAD | 24.96% |
| 2018 Q1 | -759.81 Thousand CAD | 22.65% |
| 2018 Q2 | -981.7 Thousand CAD | -29.2% |
| 2017 Q1 | -300.73 Thousand CAD | -64.42% |
| 2017 FY | -2.58 Million CAD | -4.77% |
| 2017 Q4 | -982.25 Thousand CAD | -52.63% |
| 2017 Q3 | -643.54 Thousand CAD | 2.89% |
| 2017 Q2 | -662.72 Thousand CAD | -120.37% |
| 2016 Q3 | -977.88 Thousand CAD | -50.86% |
| 2016 Q1 | -662.45 Thousand CAD | 25.08% |
| 2016 Q2 | -648.19 Thousand CAD | 2.15% |
| 2016 Q4 | -182.91 Thousand CAD | 81.3% |
| 2016 FY | -2.47 Million CAD | 13.39% |
| 2015 Q2 | -682.88 Thousand CAD | -6.93% |
| 2015 FY | -2.85 Million CAD | -2.15% |
| 2015 Q4 | -884.23 Thousand CAD | -31.54% |
| 2015 Q1 | -638.64 Thousand CAD | 7.07% |
| 2015 Q3 | -672.24 Thousand CAD | 1.56% |
| 2014 Q1 | -608.92 Thousand CAD | -9.75% |
| 2014 Q2 | -761.26 Thousand CAD | -25.02% |
| 2014 Q3 | -736.14 Thousand CAD | 3.3% |
| 2014 FY | -2.79 Million CAD | -35.27% |
| 2014 Q4 | -687.19 Thousand CAD | 6.65% |
| 2013 Q4 | -554.82 Thousand CAD | -39.66% |
| 2013 FY | -2.06 Million CAD | 20.67% |
| 2013 Q2 | -569.51 Thousand CAD | -4.78% |
| 2013 Q3 | -397.25 Thousand CAD | 30.25% |
| 2013 Q1 | -543.54 Thousand CAD | 22.4% |
| 2012 Q1 | -627.71 Thousand CAD | -25.92% |
| 2012 Q2 | -686.49 Thousand CAD | -9.36% |
| 2012 FY | -2.6 Million CAD | -27.41% |
| 2012 Q4 | -700.41 Thousand CAD | -18.96% |
| 2012 Q3 | -588.76 Thousand CAD | 14.24% |
| 2011 FY | -2.04 Million CAD | -10.77% |
| 2011 Q1 | -573.11 Thousand CAD | -16.43% |
| 2011 Q2 | -571.91 Thousand CAD | 0.21% |
| 2011 Q3 | -423.07 Thousand CAD | 26.03% |
| 2011 Q4 | -498.51 Thousand CAD | -17.83% |
| 2010 Q2 | -425.01 Thousand CAD | 5.19% |
| 2010 Q3 | -478.87 Thousand CAD | -12.67% |
| 2010 Q1 | -448.29 Thousand CAD | 6.92% |
| 2010 FY | -1.84 Million CAD | -24.09% |
| 2010 Q4 | -492.23 Thousand CAD | -2.79% |
| 2009 Q3 | -342.67 Thousand CAD | 10.78% |
| 2009 Q2 | -384.08 Thousand CAD | -38.05% |
| 2009 Q1 | -278.22 Thousand CAD | 48.57% |
| 2009 FY | -1.48 Million CAD | 47.54% |
| 2009 Q4 | -481.59 Thousand CAD | -40.54% |
| 2008 Q1 | -644.19 Thousand CAD | 37.45% |
| 2008 Q4 | -540.97 Thousand CAD | -9.12% |
| 2008 Q3 | -495.77 Thousand CAD | 54.98% |
| 2008 Q2 | -1.1 Million CAD | -70.96% |
| 2008 FY | -2.83 Million CAD | 23.77% |
| 2007 Q3 | -1.09 Million CAD | 4.69% |
| 2007 Q2 | -1.14 Million CAD | -153.09% |
| 2007 Q1 | -454.31 Thousand CAD | -15003.56% |
| 2007 Q4 | -1.02 Million CAD | 6.01% |
| 2007 FY | -3.71 Million CAD | -178.25% |
| 2006 Q3 | -142.87 Thousand CAD | 87.38% |
| 2006 Q2 | -1.13 Million CAD | -1028.35% |
| 2006 Q1 | -100.3 Thousand CAD | -13.06% |
| 2006 Q4 | -3008.00 CAD | 97.89% |
| 2006 FY | -1.33 Million CAD | -213.85% |
| 2005 FY | -425.66 Thousand CAD | 30.58% |
| 2005 Q3 | -77.42 Thousand CAD | 51.35% |
| 2005 Q4 | -88.71 Thousand CAD | -14.58% |
| 2005 Q1 | -80.73 Thousand CAD | 52.95% |
| 2005 Q2 | -159.13 Thousand CAD | -97.1% |
| 2004 Q4 | -171.61 Thousand CAD | -77.03% |
| 2004 Q2 | -164.54 Thousand CAD | 8.65% |
| 2004 FY | -613.21 Thousand CAD | 13.61% |
| 2004 Q3 | -96.94 Thousand CAD | 41.08% |
| 2004 Q1 | -180.11 Thousand CAD | -86.09% |
| 2003 Q3 | -85.45 Thousand CAD | 65.45% |
| 2003 FY | -709.85 Thousand CAD | 52.55% |
| 2003 Q2 | -247.31 Thousand CAD | 11.76% |
| 2003 Q1 | -280.29 Thousand CAD | -16.04% |
| 2003 Q4 | -96.78 Thousand CAD | -13.26% |
| 2002 Q2 | -467.51 Thousand CAD | -1.14% |
| 2002 Q1 | -462.24 Thousand CAD | 0.0% |
| 2002 Q4 | -241.55 Thousand CAD | 25.64% |
| 2002 FY | -1.49 Million CAD | 30.08% |
| 2002 Q3 | -324.83 Thousand CAD | 30.52% |
| 2001 FY | -2.13 Million CAD | -350.69% |
| 2000 FY | -474.8 Thousand CAD | -1452.61% |
| 1999 FY | -30.58 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -3174.731% |
| Skye Bioscience, Inc. | -13.67 Million USD | -200.843% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 150.25% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1744.522% |
| Qrons Inc. | -643.67 Thousand USD | -6289.947% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -428.741% |
| CSL Limited | 3.7 Billion USD | 101.111% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -130.462% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -715.358% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5887.425% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 25.901% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -9799.566% |
| Rebus Holdings, Inc. | -664 Thousand USD | -6094.37% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2979.951% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -10457.953% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -159.176% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 42.704% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 936.871% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -15615.144% |
| SQZ Biotechnologies Company | -75.82 Million USD | 45.756% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1342.923% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2577.689% |
| Mesoblast Limited | -84.14 Million USD | 51.121% |
| Marizyme, Inc. | -34.08 Million USD | -20.665% |
| Genus plc | 6.4 Million USD | 742.666% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 522.179% |
| Pharming Group N.V. | -4.87 Million USD | -742.919% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1970.529% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -4316.094% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -392.582% |
| ContraFect Corporation | -56.88 Million USD | 27.7% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -803.032% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2833.729% |
| IMV Inc. | -38.67 Million USD | -6.359% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1395.203% |
| MultiCell Technologies, Inc. | -722.81 USD | -5690277.416% |
| ONE Bio Corp. | 13.68 Million USD | 400.628% |
| Accustem Sciences Inc. | -3.74 Million USD | -997.865% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 30.275% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -8414.563% |
| Q BioMed Inc. | -3.44 Million USD | -1093.709% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1261.882% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1465.377% |
| Biomind Labs Inc. | -1 Million USD | -3973.94% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 25.179% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1317.686% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -518.69% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -2106.14% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -137221.772% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -2028.242% |
| GB Sciences, Inc. | -1.42 Million USD | -2795.484% |
| Alpha Cognition Inc. | -9.7 Million USD | -323.782% |
| HST Global, Inc. | -140.9 Thousand USD | -29089.903% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -3556.36% |
| Halberd Corporation | -75.05 Thousand USD | -54704.286% |
| Enzolytics Inc. | -2.14 Million USD | -1814.12% |
| Agentix Corp. | -1.37 Million USD | -2898.392% |
| Resverlogix Corp. | -12.74 Million USD | -222.618% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1198.203% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 90.323% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -3839.714% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1308.851% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -2504.267% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1107.955% |
| AVAX Technologies, Inc. | 6.69 Million USD | 714.543% |
| Zenith Capital Corp. | -8.94 Million USD | -359.92% |
| Genscript Biotech Corporation | -415.79 Million USD | 90.108% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -235997.911% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1575.165% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -23881.533% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1951.651% |
| Kadimastem Ltd | -3.04 Million USD | -1252.87% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -4079.716% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -22563.37% |
| LadRx Corporation | -3.82 Million USD | -975.697% |
| Cell Source, Inc. | -4.32 Million USD | -850.921% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5887.425% |
| NovAccess Global Inc. | -2.46 Million USD | -1567.394% |
| Affymax, Inc. | -15.04 Million USD | -173.366% |
| Itoco Inc. | -919.14 Thousand USD | -4374.902% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -870.425% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3575.658% |
| Mobile Lads Corp. | -554.55 Thousand USD | -7316.936% |
| CytoDyn Inc. | -18.05 Million USD | -127.77% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -163311.271% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -18589.109% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -7183.326% |
| SYBLEU INC | -149.18 Thousand USD | -27471.134% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -2164.503% |
| International Stem Cell Corporation | -663 Thousand USD | -6103.713% |
| Bioxytran, Inc. | -3.82 Million USD | -976.676% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -78035.671% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -202115.423% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -13.414% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -2442.065% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -5489.652% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1222.103% |
| Neutra Corp. | -229.48 Thousand USD | -17822.931% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -134.509% |
| PureTech Health plc | -146.19 Million USD | 71.867% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -91.384% |
| IXICO plc | -1.43 Million USD | -2762.256% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -333.364% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 66.233% |
| CSL Limited | 3.81 Billion USD | 101.079% |
| Cellectis S.A. | -108.85 Million USD | 62.216% |